Results 251 to 260 of about 400,631 (298)
Some of the next articles are maybe not open access.

Pharmacokinetics of ceftizoxime

European Journal of Clinical Pharmacology, 1985
The kinetics of ceftizoxime, a newly developed cephalosporin, were evaluated in 6 healthy subjects, with respect to its excretory pathways especially by the biliary route. Total, renal and biliary clearance were determined at two different steady states.
U, Gundert-Remy   +3 more
openaire   +2 more sources

Pharmacokinetics and Immunotoxicity

1980
The possibilities of different actions of xenobiotics on the immunological system are described (different cells with immunocompetence in distinct stages of development, indirect action, pharmacokinetics and especially biotransformation). Results concerning the toxic action and biotransformation are given for DOTC. The atrophy of the thymus produced by
P, Lange, G, Hennighausen, U, Karnstedt
openaire   +2 more sources

Pharmacokinetics of Peginterferons

Seminars in Liver Disease, 2003
Two polyethylene glycol (PEG)-modified interferons are approved for the treatment of chronic hepatitis C. The pharmocokinetic properties of the branched 40 kDa pegylated interferon alfa-2a differ from the linear 12 kDa pegylated interferon alfa-2b.
Stefan, Zeuzem   +2 more
openaire   +2 more sources

Pharmacokinetics of desogestrel

American Journal of Obstetrics and Gynecology, 1993
A synthetic form of desogestrel, a gonane progestin, was developed because desogestrel's enhanced selectivity eliminates adverse, androgen-dependent, metabolic effects at contraceptive doses. Desogestrel is rapidly and completely metabolized in the liver and gut wall to 3-keto-desogestrel, which is the active metabolite mediating the progestin effects.
H D, McClamrock, E Y, Adashi
openaire   +2 more sources

Pharmacokinetics of terazosin

The American Journal of Medicine, 1986
The pharmacokinetics of terazosin have been assessed in human volunteers, hypertensive patients, a limited number of elderly volunteers, and a small number of patients with congestive heart failure. Terazosin was administered intravenously and orally in doses ranging up to 7.5 mg.
openaire   +2 more sources

Ritodrine pharmacokinetics

Clinical Pharmacology and Therapeutics, 1986
The purpose of this study was to add to the limited information available regarding the pharmacology of ritodrine in the peripartum period when treatment fails and labor is not inhibited. Plasma or urine samples from eight parturients and 13 infants were studied; in addition plasma samples at delivery were obtained from a total of 26 mothers and ...
B R, Kuhnert   +4 more
openaire   +2 more sources

Pharmacokinetics of the Taxanes

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997
The pharmacokinetics of the taxanes paclitaxel and docetaxel have been studied extensively in humans. Paclitaxel has distinctly nonlinear pharmacokinetics, with saturable distribution and elimination features. Docetaxel pharmacokinetics are well described by linear processes, although some investigators detected subtle nonlinear characteristics ...
openaire   +2 more sources

Pharmacokinetics of prostaglandins

Best Practice & Research Clinical Obstetrics & Gynaecology, 2003
Naturally occurring prostaglandins (PGs) are rapidly metabolized in the human circulation. For clinical use a number of PG analogues have therefore been developed which are resistant to rapid inactivation. Among these are carboprost, gemeprost and misoprostol.
openaire   +2 more sources

Lamotrigine: Pharmacokinetics

Journal of Child Neurology, 1997
The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy. Lamotrigine exhibits first-order linear pharmacokinetics. Lamotrigine is well absorbed with bioavailability approaching 100%. The absorption is unaffected by food and there is no first-pass metabolism. The
openaire   +2 more sources

Psychopharmacology and pharmacokinetics

2019
The overall physiologic changes associated with aging lead to changes in both pharmacokinetic and pharmacodynamic actions of many medications. This, in turn, leads to changes in the impact that a wide variety of medications have on older adults when compared to younger, healthy individuals. These pharmacokinetic and pharmacodynamic variations can cause
Jacob, Tillmann, Ashley, Reich
openaire   +2 more sources

Home - About - Disclaimer - Privacy